Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Neuren PharmaceuticalsASX:NEU +3.28%48 EV-to-EBIT is 93.66 as of Aug. 03, 2026, which is 395% above its 10-year median of 18.94. GuruFocus rates ASX:NEU with a GF Score™ of 48/100 and a GF Value™ of A$7.33 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 387 Biotechnology companies, Neuren Pharmaceuticals ranks worse than 92.76% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Neuren Pharmaceuticals's Enterprise Value for the quarter that ended in Dec. 2025 was A$2,060.65 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Neuren Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$22.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:NEU vs VRTX, REGN, RVMD: EV-to-EBIT Comparison
For the Biotechnology subindustry, Neuren Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neuren Pharmaceuticals EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Neuren Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Neuren Pharmaceuticals's EV-to-EBIT falls into.
Neuren Pharmaceuticals's current Enterprise Value is A$2,060.61 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Neuren Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was A$22.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neuren Pharmaceuticals (ASX:NEU) has a EV-to-EBIT of 93.66 as of Aug. 03, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Neuren Pharmaceuticals and its competitors. This is 395% above median its historical median of 18.94. According to the industry distribution chart, Neuren Pharmaceuticals ranks #359 out of 387 companies in the Biotechnology industry, placing it in the top 92.8%.
Is Neuren Pharmaceuticals' EV-to-EBIT too high?
Neuren Pharmaceuticals' current EV-to-EBIT of 93.66 is 395% above median its 10-year median of 18.94. The Biotechnology industry median EV-to-EBIT is 12.63. Neuren Pharmaceuticals' value of 93.66 is 641.6% above this industry median. Based on the distribution chart, Neuren Pharmaceuticals ranks #359 out of 387 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Neuren Pharmaceuticals has a GF Score™ of 48/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Neuren Pharmaceuticals' EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Neuren Pharmaceuticals ranks #359 out of 387 companies for EV-to-EBIT. This places Neuren Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBIT is 12.63. Neuren Pharmaceuticals' value of 93.66 is 641.6% above this benchmark. While the company's 10-year median is 18.94 vs. the industry median of 12.63, Neuren Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 12.63, based on 387 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neuren Pharmaceuticals's current EV-to-EBIT of 93.66 is 641.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Neuren Pharmaceuticals and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 12.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neuren Pharmaceuticals's current EV-to-EBIT is 93.66, which is 395% above median its own 10-year median of 18.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuren Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Neuren Pharmaceuticals (ASX:NEU) is currently considered Significantly Overvalued. The stock's GF Value™ is A$7.33, compared to a current price of A$18.59 — trading 153.6% above its estimated fair value. The current EV-to-EBIT is 93.66, which is 395% above median its 10-year median of 18.94 and 641.6% above the Biotechnology industry median of 12.63. Neuren Pharmaceuticals' overall GF Score™ is 48/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Neuren Pharmaceuticals (ASX:NEU), the current EV-to-EBIT is 93.66 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neuren Pharmaceuticals (ASX:NEU) Overvalued in 2026?
Based on GuruFocus' analysis, Neuren Pharmaceuticals stock appears to be overvalued.
The current stock price of A$18.59 is trading 153.6% above its estimated GF Value™ of A$7.33.
GuruFocus considers Neuren Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for ASX:NEU:
EV-to-EBIT: 93.66 (395% above median its 10-year median of 18.94)
GF Value™: A$7.33 vs. price of A$18.59 (153.6% above fair value)
Industry Position: 641.6% above the Biotechnology median (#359 of 387)
No single metric tells the full story. See the ASX:NEU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neuren Pharmaceuticals Ltd is a biopharmaceutical company, which engages in the development of new therapies for brain injury, neurodevelopment disorders. Its drugs target symptoms resulting from acute traumatic brain injury, as well as symptoms of chronic conditions, such as Rett syndrome and Fragile X syndrome. The Group has two reportable operating segments, Commercial Products and Research and Development. It derives maximum revenue from Commercial Products.
48GF Score
Get the complete analysis for ASX:NEU
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:NEU has been successfully added to your 
